CLX Stock Slips As Margin Pressure Triggers Fresh Target Cuts

Clorox Company (The) stocks have been trading down by -4.01 percent amid heightened concerns over supply-chain disruptions and rising costs.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CLX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q4 gross margin for CLX dropped 520 bps year over year to 41.3%, hurt by lower volumes, GOJO acquisition costs, pricier commodities, and higher manufacturing and logistics spending.
RBC Capital Markets now expects fiscal 2027 sales for Clorox Company (The) to rise 13.5%, but sees real underlying growth stuck around 0–1%, and cut its FY27 EPS outlook alongside a lower price target.
HSBC slashed its CLX price target to $104 from $129, while the wider Street sits at an average Hold rating and roughly $98 mean target, versus a current price near $102.39.
Several major firms — including JPMorgan, Barclays, and Evercore ISI — keep Underweight or Underperform calls on CLX, with targets in the mid-$80s to mid-$90s, all below the $98–$99 consensus zone.
Bank of America trimmed its Clorox target to $100 from $102, flagging rising pressures and an unusually wide, cautious fiscal 2027 EPS guidance range from management.

Live Update At 12:32:36 EDT: On Monday, August 31, 2026 Clorox Company (The) stock [NYSE: CLX] is trending down by -4.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CLX has been bleeding slowly on the chart. Over the last couple of weeks, Clorox Company (The) has faded from the $107 area to a recent close near $98.42, breaking below the psychological $100 level. That’s a clean downtrend, not a random wiggle.

Intraday, the 5‑minute tape shows CLX opening around $102.17 before getting sold down into the high‑$98s, with tight, choppy candles between $98.3 and $99.0 for most of the session. That tells traders supply is in control and dips are not snapping back with real strength.

More Breaking News

Fundamentally, CLX is paying for past glory. Revenue over the last few years is slightly shrinking, yet the stock still trades at about 21x earnings and 1.85x sales. The balance sheet is heavy: total debt is high, interest coverage is thin at 1.8, and the current ratio is only 0.7. CLX does throw off cash — free cash flow of roughly $244M and a dividend near 4.9% — but that comes with tight liquidity and leverage. For active traders, CLX looks more like a slow grinder than a clean momentum breakout, with risk skewed toward more mean reversion than runaway upside.

Why Traders Are Watching CLX Now

What has the Street nervous is not just the CLX chart, it’s the earnings quality underneath. Clorox Company (The) reported a sharp 520 basis‑point year‑over‑year drop in Q4 gross margin to 41.3%. For a consumer staples name, that’s a big move. Lower volumes, the GOJO acquisition step‑up, higher commodities, and pricier manufacturing and logistics all hit at once. Cost savings helped, but not enough to stop the bleed.

RBC Capital Markets laid out the longer‑term worry clearly. RBC sees fiscal 2027 CLX sales rising 13.5%, but says the real underlying growth is basically flat, maybe 1% at best. Translation for traders: a lot of that growth comes from deals and pricing, not a healthy demand engine. RBC cut its FY27 EPS estimate and trimmed its CLX target while sticking with a Sector Perform view — not a disaster call, but not a green light either.

On top of that, pricing from the big banks keeps sliding. HSBC chopped its CLX target to $104 from $129, even as the stock trades around $102.39, above the mean Street target of roughly $98. Multiple houses — JPMorgan, Barclays, Evercore ISI — stay Underweight or Underperform, with price targets spanning roughly $84 to $99. Jefferies and Bank of America sit closer to the middle with Hold and Neutral ratings near $100, but they’re not pounding the table. The overall message to traders is clear: CLX is no longer a pandemic darling; it’s a crowded, fairly priced defensive name facing real margin and demand pressure.

Conclusion

For active traders, CLX is a classic lesson in why you never fall in love with a ticker. Clorox Company (The) still owns strong brands, but the numbers show tightening margins, sluggish organic growth, and mounting cost pressure. When gross margin drops 520 bps in a year and guidance for 2027 EPS is wide and cautious, the Street takes notice — and so should anyone trading around CLX.

The valuation gap is narrow. CLX trades modestly above the average target near $98, while major firms like HSBC, JPMorgan, and Barclays lean cautious with targets below or just around current levels. That sets up a risk profile where downside surprises hit harder than upside beats. The daily chart confirms it: lower highs, a break of $100, and a heavy intraday tape.

For the Tim Sykes‑style trader, the playbook is simple: respect the trend, focus on key levels, and do not marry the story. As Tim loves to say, “The market doesn’t care about your opinion, only your discipline.” That lines up with the broader trading mindset that you only act when the setup is truly there. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. With CLX, that means treating every bounce as a potential short‑term trading setup — not a guarantee of a turnaround — and always being ready to cut losses fast if the tape flips against you. This is educational and research content, not a signal, but the message from CLX right now is discipline over hope.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!